WO2018150395A3 - 4-n-butylresorcinol preparations - Google Patents

4-n-butylresorcinol preparations Download PDF

Info

Publication number
WO2018150395A3
WO2018150395A3 PCT/IB2018/052742 IB2018052742W WO2018150395A3 WO 2018150395 A3 WO2018150395 A3 WO 2018150395A3 IB 2018052742 W IB2018052742 W IB 2018052742W WO 2018150395 A3 WO2018150395 A3 WO 2018150395A3
Authority
WO
WIPO (PCT)
Prior art keywords
skin
agents
concentration
treatment
formulation
Prior art date
Application number
PCT/IB2018/052742
Other languages
French (fr)
Other versions
WO2018150395A2 (en
WO2018150395A4 (en
Inventor
Natalie Laura ECHEVERRIA
Original Assignee
HAKKI, Erkan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HAKKI, Erkan filed Critical HAKKI, Erkan
Priority to GBGB1909518.1A priority Critical patent/GB201909518D0/en
Publication of WO2018150395A2 publication Critical patent/WO2018150395A2/en
Publication of WO2018150395A3 publication Critical patent/WO2018150395A3/en
Publication of WO2018150395A4 publication Critical patent/WO2018150395A4/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42Amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/347Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

A medical or cosmetic formulation such as pastes, gels, lotions, serums, creams, peels and sprays comprising 4-n-butylresorcinol in a concentration greater than substantially 18% preferably between substantially 20% and substantially 60% diluted with a hydrophilic agent, or any diluent known in the art, can be used for treating various skin conditions, e.g. complexion, hyperpigmentation, melasma, pore size, skin density, hydration, superficial scars, post-operative scars, hypertrophic and atrophic scars, post-inflammatory hyperpigmentation, solar lentigines, acne vulgaris and as an anti-aging treatment. The formulae include peels and skincare using various delivery systems, such as liposomal delivery systems and all agents to aide penetration of the epidermis, known in the art. Compositions may include preservatives, such as levulinic acid. Formulation embodiments of the invention can have any one or more of the following features: • Said formulation is between substantially 18% and substantially 60% • Said concentration to produce a skincare treatment • Said concentration to produce a mild peel • Said concentration to produce a medium peel • Said concentration to produce a deep peel • For use in the treatment of any or more of the group comprising: complexion, anti-aging, hyperpigmentation skin disorders, atrophic and hypertrophic superficial and post-operative scars, hydration, skin density, pore size, acne vulgaris • Comprising any one or more of the ingredients mentioned herein for the treatment of melasma • Comprising any one or more of the ingredients mentioned herein for the treatment of hyperpigmentory skin disorders • Another aspect of the invention consists in a method of treating the skin, in which there is used a formulation embodying the invention • A formulation consisting any one of the following: DMSO, levulinic acid, fatty acids such as oleic acid, coconut oil, sources of vitamin C, e.g. rosehip seed, camu camu, infection control such as natural antibiotics e.g. colloidal silver, hydration agents such as glycerin and hyaluronic acid, walnuts, opti zinc, inhibition of collagen synthesis, healing agents such as croton lechleri, tyrosine kinase inhibitors, calcium antagonists such as magnesium, antioxidants such as r lipoic acid, astaxanthin and ubiquinol coqlO, telomeres lengthening agents such as resveratrol and cycloastrogenol, TGF-b inhibitors, protein kinase C (PKC) inhibitors, scar reduction agents such as niacinamide, anti¬ inflammatories such as white willow bark, bamboo, cannabinoids, watermelon skin, agents for collagen stimulation, anti-glycation, immune pathways, red spinach, cherry blossom, tormentil, chitin, rambutan, amino acids, (GL1), (GL3), (TTG1), soursop, oleuropein, cassia, apple skin, osmanthus and all anti-aging agents known in the art. These additional components, may be combined with 4-n-butylresorcinol or may be used separately.
PCT/IB2018/052742 2017-02-20 2018-04-20 4-n-butylresorcinol preparations WO2018150395A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB1909518.1A GB201909518D0 (en) 2017-02-20 2018-04-20 4-N-Butylresorcinol preparations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1702690.7A GB2562991A (en) 2017-02-20 2017-02-20 4-N butylresorcinol in a skincare formulation in concentrations of twenty percent, up to and including sixty percent
GB1702690.7 2017-02-20

Publications (3)

Publication Number Publication Date
WO2018150395A2 WO2018150395A2 (en) 2018-08-23
WO2018150395A3 true WO2018150395A3 (en) 2018-10-25
WO2018150395A4 WO2018150395A4 (en) 2018-12-13

Family

ID=58486765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/052742 WO2018150395A2 (en) 2017-02-20 2018-04-20 4-n-butylresorcinol preparations

Country Status (2)

Country Link
GB (2) GB2562991A (en)
WO (1) WO2018150395A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109528730A (en) * 2018-12-11 2019-03-29 江苏永健医药科技有限公司 Application of the cycloastragenol in preparation prevention or Retinoids, Retin-A, Renova, Accutane
CN110227044A (en) * 2019-05-12 2019-09-13 广州芊舟生物科技有限公司 A kind of HA collagen stoste and preparation method thereof
CN111662737B (en) * 2019-11-28 2021-09-07 中国海洋大学 Application of pyroligneous liquor medium-temperature-section rectification component in reduction of antibiotic resistance gene contaminated soil

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001206813A (en) * 2000-01-27 2001-07-31 Pola Chem Ind Inc Skin preparation for external use for physical therapy
US20100215594A1 (en) * 2007-08-13 2010-08-26 Merck Patent Gmbh Tyrosinase Inhibitors
US20110274727A1 (en) * 2008-10-28 2011-11-10 Galderma Research & Development Depigmenting topical compositions and their uses
US20120093749A1 (en) * 2009-05-14 2012-04-19 Pierre Fabre Dermo-Cosmetique Use of delta-tocopheryl-carbohydrate as a depigmenting agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001206813A (en) * 2000-01-27 2001-07-31 Pola Chem Ind Inc Skin preparation for external use for physical therapy
US20100215594A1 (en) * 2007-08-13 2010-08-26 Merck Patent Gmbh Tyrosinase Inhibitors
US20110274727A1 (en) * 2008-10-28 2011-11-10 Galderma Research & Development Depigmenting topical compositions and their uses
US20120093749A1 (en) * 2009-05-14 2012-04-19 Pierre Fabre Dermo-Cosmetique Use of delta-tocopheryl-carbohydrate as a depigmenting agent

Also Published As

Publication number Publication date
WO2018150395A2 (en) 2018-08-23
GB2562991A (en) 2018-12-05
GB201702690D0 (en) 2017-04-05
WO2018150395A4 (en) 2018-12-13
GB201909518D0 (en) 2019-08-14

Similar Documents

Publication Publication Date Title
US11426442B2 (en) Compositions and methods for invasive and non-invasive procedural skincare
US9000049B2 (en) Combination of lycopene, polyphenol, and vitamins for the care of keratin materials
WO2018150395A3 (en) 4-n-butylresorcinol preparations
US20160074353A1 (en) Use of petroselinic acid to fight against aesthetic disorders of the body figure
Glass Cosmeceuticals: the principles and practice of skin rejuvenation by nonprescription topical therapy
WO2014030117A4 (en) Cosmetic use of the essential oil of laserpitium siler l. against the signs of aging of the skin and as a skin antioxidant
US10729896B2 (en) Delivery and induction of therapeutic agents and uses thereof
KR102472978B1 (en) Composition for improving skin
KR101661288B1 (en) Composition for improving skin
WO2013130056A1 (en) Use of starfruit extract as a cpt-1 modulator and compositions thereof
JP2014144929A (en) Composition containing vitamins for preventing or treating acne
Farrisa Cosmeceuticals for Acne and Rosacea
Lupo et al. Cosmeceuticals for enhancing cosmetic procedures
Gupta Party peels
Do et al. Exploring the skin whitening properties of natural products: A comprehensive review
Glass of Skin Rejuvenation by Nonprescription Topical Therapy
JP2007238588A (en) Mixed cream for preventing and ameliorating beautiful skin effect, varicose vein of lower extremity and skin cancer
Talakoub et al. Antiaging Cosmeceuticals
KR20150087144A (en) Composition for improving skin
Wollina et al. Minimally Invasive Upper Arm Contouring in Esthetic Medicine
KR20160128765A (en) Composition for improving skin
Bowes Exploring the science of cosmeceuticals used to achieve optimal skin health
MX2021015351A (en) Formulations for odontological and dermatological use containing trichloroacetate salts and hydroxyacids.
Traill et al. Managing photodamage with topical skincare ingredients and chemical peels
Sadick 32 Future Cosmeceuticals of Dermatologic Importance

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18737972

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018737972

Country of ref document: EP

Effective date: 20190920

122 Ep: pct application non-entry in european phase

Ref document number: 18737972

Country of ref document: EP

Kind code of ref document: A2